Infection in Immunocompromised Hosts

Infection in Immunocompromised Hosts

Infection in Immunocompromised Hosts

On this page

Immunocompromise Basics - Setting the Stage

  • Definition: Immune system's ↓ ability to fight infections & malignancies. Understanding this is crucial for risk stratification & guiding prophylactic/empirical therapy.
  • Etiology:
    • Primary (Congenital): Rare genetic defects (e.g., SCID, CVID, DiGeorge Syndrome).
    • Secondary (Acquired): More prevalent; develops due to external factors.
      • HIV/AIDS (CD4 count < 200 cells/µL defines AIDS).
      • Hematological malignancies (leukemia, lymphoma) & solid tumors.
      • Solid organ or hematopoietic stem cell transplant recipients.
      • Immunosuppressive therapy: Corticosteroids (e.g., prednisone ≥20mg/day for ≥2 weeks), chemotherapy, biologics (e.g., TNF-α inhibitors).
      • Chronic diseases: Diabetes mellitus, chronic kidney disease, malnutrition, asplenia.
  • Key Cellular Deficits & Implications:
    • Neutropenia: Absolute Neutrophil Count (ANC) < 1500/µL; severe if < 500/µL (↑ risk of bacterial/fungal infections).
    • Lymphopenia: T-cell defects (cellular immunity) → opportunistic infections (fungi, viruses, protozoa). B-cell defects (humoral immunity) → sinopulmonary bacterial infections. Causes of Immunodeficiency and Associated Malignancies

⭐ HIV infection is a major cause of acquired immunodeficiency globally, leading to a spectrum of opportunistic infections as CD4 count declines below 200 cells/µL (AIDS-defining).

Immune DefectCommon Pathogens
Neutropenia (<500/µL)Gram-neg rods (esp. Pseudomonas aeruginosa), Staphylococcus aureus, Fungal (Candida spp., Aspergillus spp.).
T-cell Defect (Cellular)Pneumocystis jirovecii (PJP), CMV, HSV, VZV, Cryptococcus neoformans, Listeria monocytogenes, Mycobacterium spp., Toxoplasma gondii, Nocardia spp.
B-cell Defect (Humoral)Encapsulated: S. pneumoniae, H. influenzae type b, N. meningitidis; Giardia lamblia, Enteroviruses.
Asplenia / SplenectomyEncapsulated: S. pneumoniae, H. influenzae type b, N. meningitidis; Capnocytophaga canimorsus, Babesia spp.
Complement (Early C1-C4)Encapsulated bacteria, ↑ SLE risk.
Complement (Late C5-C9 MAC)Recurrent Neisseria spp. infections.

Febrile Neutropenia - Fever Alarm!

  • Definition: Fever (single oral T ≥ 38.3°C or T ≥ 38.0°C sustained for ≥1 hr) + Neutropenia (ANC < 500/mm³, or < 1000/mm³ with predicted nadir < 500/mm³).
  • Risk Stratification:
    • MASCC Score: Low risk (≥21), High risk (<21).
    • High risk criteria also include: prolonged neutropenia (>7 days), significant comorbidities.
  • Initial Management: Empiric broad-spectrum antibiotics within 1 hour.
    • High Risk: IV anti-pseudomonal β-lactam (e.g., Cefepime, Piperacillin-Tazobactam, Meropenem).
    • Low Risk: Consider oral (e.g., Ciprofloxacin + Amoxicillin-Clavulanate) or IV.
  • Common Pathogens: Pseudomonas, E. coli, Klebsiella, Staphylococcus, Streptococcus.

⭐ Empiric antibiotic therapy must cover Pseudomonas aeruginosa.

Prophylaxis Strategies - Defense First!

  • Goal: Prevent Opportunistic Infections (OIs) in vulnerable hosts.
  • PCP (Pneumocystis jirovecii Pneumonia):
    • TMP-SMX (preferred).
    • Indications: HIV CD4 < 200/μL; post-transplant; prolonged high-dose corticosteroids.
  • Toxoplasmosis:
    • TMP-SMX for Toxoplasma gondii IgG+ HIV patients, CD4 < 100/μL.
  • MAC (Mycobacterium Avium Complex):
    • Azithromycin or Clarithromycin for HIV CD4 < 50/μL.
  • Fungal Infections:
    • Antifungals (e.g., Fluconazole, Posaconazole) for HSCT, prolonged neutropenia.
  • Viral (CMV, HSV/VZV):
    • Antivirals (e.g., Ganciclovir, Acyclovir) post-transplant, severe T-cell defects.
  • Vaccinations:
    • Essential: Pneumococcal, Influenza (inactivated), Hepatitis B.
    • ⚠️ Avoid live vaccines if severely immunocompromised.

⭐ TMP-SMX is cornerstone for PCP prophylaxis; also covers Toxoplasmosis & Nocardiosis.

High‑Yield Points - ⚡ Biggest Takeaways

  • Neutropenia (ANC < 500/mm³): risk of bacterial (Pseudomonas) & fungal (Aspergillus, Candida) infections.
  • T-cell defects (HIV, steroids): risk of PJP, CMV, Cryptococcus, Toxoplasma.
  • HIV CD4 counts guide OI risk: PJP <200, Toxo/Crypto <100, CMV/MAC <50.
  • Key prophylaxis: TMP-SMX for PJP/Toxo; antifungals for severe neutropenia.
  • Invasive aspergillosis: halo/crescent sign (CT), treat with voriconazole.
  • PJP: diffuse infiltrates, ↑LDH, treat/prophylax with TMP-SMX.
  • Cryptococcal meningitis: India ink/antigen positive, treat with Amphotericin B + Flucytosine.

Practice Questions: Infection in Immunocompromised Hosts

Test your understanding with these related questions

WHO AIDS defining illnesses are all EXCEPT:

1 of 5

Flashcards: Infection in Immunocompromised Hosts

1/10

_____ and diabetic patients are especially susceptible to Mucormycosis infections

TAP TO REVEAL ANSWER

_____ and diabetic patients are especially susceptible to Mucormycosis infections

Immuno-compromised (ie: those on glucocorticoids, HIV+/AIDS)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial